Targeting carcinoembryonic antigen-expressing tumors using a novel transcriptional and translational dual-regulated oncolytic herpes simplex virus type 1.
HSV-1
VG2025
cancer vaccine
immunotherapy
interleukin-12
interleukin-15
intravenous delivery
microRNA
oncolytic virus
virotherapy
Journal
Molecular therapy oncolytics
ISSN: 2372-7705
Titre abrégé: Mol Ther Oncolytics
Pays: United States
ID NLM: 101666776
Informations de publication
Date de publication:
16 Mar 2023
16 Mar 2023
Historique:
received:
18
08
2022
accepted:
07
02
2023
entrez:
20
3
2023
pubmed:
21
3
2023
medline:
21
3
2023
Statut:
epublish
Résumé
VG2025 is a recombinant oncolytic herpes simplex virus type 1 (HSV-1) that uses transcriptional and translational dual regulation (TTDR) of critical viral genes to enhance virus safety and promote tumor-specific virus replication without reducing virulence. The TTDR platform is based on transcriptional control of the essential HSV-1 immediate-early protein ICP27 using a tumor-specific carcinoembryonic antigen (CEA) promoter, coupled with translational control of the neurovirulence factor ICP34.5 using multiple microRNA (miR)-binding sites. VG2025 further incorporates IL-12 and the IL-15/IL-15 receptor alpha subunit complex to enhance the antitumor and immune stimulatory properties of oncolytic HSVs. The TTDR strategy was verified
Identifiants
pubmed: 36938544
doi: 10.1016/j.omto.2023.02.003
pii: S2372-7705(23)00011-6
pmc: PMC10018392
doi:
Types de publication
Journal Article
Langues
eng
Pagination
334-348Informations de copyright
© 2023 The Authors.
Déclaration de conflit d'intérêts
All authors are current or former (Ismael Samudio, present affiliation: Immunity Diagnostics Inc.) employees of Virogin Biotech Canada Ltd., and have ownership interest (including stock, patents, etc.) in Virogin Biotech Canada Ltd. Patent applications have been filed to cover VG2025 and related technologies. This study was wholly funded by Virogin Biotech Canada Ltd., but the study authors retained absolute discretion over the design and execution of the study, the collection, analysis, and interpretation of the data, and the writing of the manuscript. Study funding was not conditioned on the outcome of the research.
Références
Gene Ther. 2016 May;23(5):460-8
pubmed: 26905370
J Med Toxicol. 2021 Oct;17(4):411-424
pubmed: 33826117
Oncotarget. 2017 Nov 18;8(62):105936-105941
pubmed: 29285304
Sci Transl Med. 2018 Jan 3;10(422):
pubmed: 29298865
J Neurosci. 2013 Mar 20;33(12):5127-37
pubmed: 23516279
J Mol Med (Berl). 2000;78(3):166-74
pubmed: 10868479
Front Endocrinol (Lausanne). 2018 Aug 03;9:402
pubmed: 30123182
Nat Immunol. 2001 Dec;2(12):1138-43
pubmed: 11702064
Biomedicines. 2020 Nov 09;8(11):
pubmed: 33182232
Proc Natl Acad Sci U S A. 1997 Feb 4;94(3):843-8
pubmed: 9023344
Cancer Res. 2009 Apr 15;69(8):3472-81
pubmed: 19351838
CA Cancer J Clin. 2020 Mar;70(2):86-104
pubmed: 31944278
Proc Natl Acad Sci U S A. 2006 Jun 13;103(24):9166-71
pubmed: 16757567
Gene Ther. 2003 Feb;10(4):292-303
pubmed: 12595888
J Clin Oncol. 2006 Nov 20;24(33):5313-27
pubmed: 17060676
Int J Cancer. 2007 Dec 1;121(11):2443-50
pubmed: 17657737
Acta Biochim Pol. 2012;59(4):467-74
pubmed: 23173124
Curr Biol. 2002 Apr 30;12(9):735-9
pubmed: 12007417
Brain Res. 2007 Feb 2;1131(1):37-43
pubmed: 17182009
Oncotarget. 2016 May 10;7(19):28658-69
pubmed: 27070093
Transl Res. 2021 Nov;237:98-123
pubmed: 33905949
Mol Cancer Res. 2003 Oct;1(12):882-91
pubmed: 14573789
Cell Death Differ. 2015 Feb;22(2):237-46
pubmed: 25190142
J Natl Cancer Inst. 1990 Jan 3;82(1):44-7
pubmed: 1688382
J Virol. 2012 Apr;86(8):4420-31
pubmed: 22345479
Cancer Immunol Immunother. 2022 Sep;71(9):2057-2065
pubmed: 35024897
Clin Cancer Res. 2009 Aug 15;15(16):5126-35
pubmed: 19671871
J Biol Chem. 1995 Feb 24;270(8):3602-10
pubmed: 7876096
J Immunother Cancer. 2022 Apr;10(4):
pubmed: 35414592
Lancet Oncol. 2013 May;14(6):e218-28
pubmed: 23639322
Biochem Soc Trans. 2008 Dec;36(Pt 6):1224-31
pubmed: 19021530
Cytokine. 2015 Oct;75(2):261-71
pubmed: 26113402
Proc Natl Acad Sci U S A. 1995 Feb 28;92(5):1411-5
pubmed: 7877992
Arterioscler Thromb Vasc Biol. 2008 Jan;28(1):160-5
pubmed: 17951321
Mol Ther Oncolytics. 2020 Aug 08;18:476-490
pubmed: 32953982
Mol Ther. 2010 May;18(5):929-35
pubmed: 20179676
J Virol. 2017 Nov 14;91(23):
pubmed: 28904192
Cancers (Basel). 2021 Jan 06;13(2):
pubmed: 33418929
Cell Host Microbe. 2007 Mar 15;1(1):23-35
pubmed: 18005679
J Interferon Cytokine Res. 2015 Aug;35(8):585-99
pubmed: 25803788
Thorax. 1995 Jun;50(6):651-7
pubmed: 7638808
Cancers (Basel). 2021 Mar 18;13(6):
pubmed: 33803762
Cancer Res. 2005 Apr 1;65(7):2832-9
pubmed: 15805284
J Immunother Cancer. 2021 Apr;9(4):
pubmed: 33883258
Front Immunol. 2016 Oct 04;7:406
pubmed: 27757114
Cancers (Basel). 2021 Oct 29;13(21):
pubmed: 34771615
Clin Microbiol Rev. 1997 Jul;10(3):419-43
pubmed: 9227860
Semin Cancer Biol. 1999 Apr;9(2):67-81
pubmed: 10202129
Gastroenterol Res Pract. 2017;2017:7521987
pubmed: 28588612
J Virol. 1993 Apr;67(4):2396-401
pubmed: 8383250
J Biol Chem. 2013 Jun 21;288(25):18093-103
pubmed: 23649624
J Cell Mol Med. 2017 Apr;21(4):816-830
pubmed: 27860224
Br J Cancer. 2013 Feb 19;108(3):662-7
pubmed: 23322207
Mol Ther Oncolytics. 2020 Aug 21;18:535-545
pubmed: 32995479
J Natl Cancer Inst. 1984 Jan;72(1):161-4
pubmed: 6582296
Br J Cancer. 1996 Sep;74(5):745-52
pubmed: 8795577
Front Immunol. 2018 Oct 23;9:2460
pubmed: 30405639
J Virol. 1994 Mar;68(3):1271-82
pubmed: 8107193
J Med Toxicol. 2022 Jan;18(1):43-55
pubmed: 33821435
Cytokine Growth Factor Rev. 2002 Apr;13(2):155-68
pubmed: 11900991